Salomon Manier

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Oksana Zavidij, Nicholas J. Haradhvala, Tarek H. Mouhieddine et al. · Nature Cancer · 2020 · 358 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Engineered nanomedicine for myeloma and bone microenvironment targeting

Archana Swami, Michaela R. Reagan, Pamela A. Basto et al. · Proceedings of the National Academy of Sciences · 2014 · 284 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · Blood · 2017 · 271 citations · Full text

Medicine, Oncology, Hematologic Oncology +9